← EU Feed

Ethyreal launches to treat the underlying cause of Graves’, TED

Ethyreal launches to treat the underlying cause of Graves’, TED

Source Summary

Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone receptor, at the Endocrine Society’s 2026 annual meeting on June 15.

Advertisement
Read Original Article